Search

Your search keyword '"Nilesh Kalariya"' showing total 9 results
Start Over Author "Nilesh Kalariya" Search Limiters Available in Library Collection
9 results on '"Nilesh Kalariya"'

1. Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy

Author

Christopher J. Ferreri, Michelle A. T. Hildebrandt, Hamza Hashmi, Leyla O. Shune, Joseph P. McGuirk, Douglas W. Sborov, Charlotte B. Wagner, M. Hakan Kocoglu, Aaron Rapoport, Shebli Atrash, Peter M. Voorhees, Jack Khouri, Danai Dima, Aimaz Afrough, Gurbakhash Kaur, Larry D. Anderson, Gary Simmons, James A. Davis, Nilesh Kalariya, Lauren C. Peres, Yi Lin, Murali Janakiram, Omar Nadeem, Melissa Alsina, Frederick L. Locke, Surbhi Sidana, Doris K. Hansen, Krina K. Patel, and Omar Alexis Castaneda Puglianini

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Most patients with multiple myeloma experience disease relapse after treatment with a B-cell maturation antigen-targeted therapy (BCMA-TT), and data describing outcomes for patients treated with sequential BCMA-TT are limited. We analyzed clinical outcomes for patients infused with standard-of-care idecabtagene vicleucel, an anti-BCMA chimeric antigen receptor (CAR) T-cell therapy, at 11 US medical centers. A total of 50 patients with prior BCMA-TT exposure (38 antibody-drug conjugate, 7 bispecific, 5 CAR T) and 153 patients with no prior BCMA-TT were infused with ide-cel, with a median follow-up duration of 4.5 and 6.0 months, respectively. Safety outcomes between cohorts were comparable. The prior BCMA-TT cohort had a lower overall response rate (74% versus 88%; p = 0.021), median duration of response (7.4 versus 9.6 months; p = 0.03), and median progression-free survival (3.2 months versus 9.0 months; p = 0.0002) compared to the cohort without prior BCMA-TT. All five patients who received a prior anti-BCMA CAR T responded to ide-cel, and survival outcomes were best for this subgroup. In conclusion, treatment with ide-cel yielded meaningful clinical responses in real-world patients exposed to a prior BCMA-TT, though response rates and durability were suboptimal compared to those not treated with a prior BCMA-TT.

Published
2023
Full Text
View/download PDF

2. Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience

Author

Hamza Hashmi, Doris K. Hansen, Lauren C. Peres, Omar Castaneda Puglianini, Ciara Freeman, Gabriel De Avila, Surbhi Sidana, Leyla Shune, Douglas W. Sborov, James Davis, Charlotte Wagner, Mehmet H. Kocoglu, Shebli Atrash, Peter Voorhees, Gary Simmons, Christopher Ferreri, Nilesh Kalariya, Larry D. Anderson Jr., Aimaz Afrough, Danai Dima, Jack Khouri, Joseph McGuirk, Fred Locke, Rachid Baz, Krina K. Patel, and Melissa Alsina

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

While response rates and survival outcomes have been very promising for idecabtagene vicleucel (ide-cel), a proportion of patients do not respond or relapse early after this B-cell maturation antigen (BCMA) targeted chimeric antigen receptor (CAR) T-cell therapy. Understanding the characteristics of these patients is important for patient selection and development of novel strategies to improve outcomes. We evaluated factors associated with early progression (progression or death due to myeloma ≤3 months after CAR T-cell infusion) in patients treated with standard of care ide-cel at 11 US academic centers. Among 211 patients that received ide-cel, 43 patients had a progressive event ≤3 months of infusion. Patients with a history of extramedullary disease, prior BCMA targeted therapy, elevated ferritin at lymphodepletion, use of bridging therapy, Hispanic ethnicity, plasma cell leukemia and t(4;14) were more likely to progress ≤3 months of infusion (P

Published
2023
Full Text
View/download PDF

3. Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment

Author

Surbhi Sidana, Lauren C. Peres, Hamza Hashmi, Hitomi Hosoya, Christopher Ferreri, Jack Khouri, Danai Dima, Shebli Atrash, Peter Voorhees, Gary Simmons, Douglas W. Sborov, Nilesh Kalariya, Vanna Hovanky, Sushma Bharadwaj, David Miklos, Charlotte Wagner, Mehmet H. Kocoglu, Gurbakhash Kaur, James A. Davis, Shonali Midha, Murali Janakiram, Ciara Freeman, Melissa Alsina, Frederick Locke, Rebecca Gonzalez, Yi Lin, Joseph McGuirk, Aimaz Afrough, Leyla Shune, Krina K. Patel, and Doris K. Hansen

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

We evaluated patients with relapsed multiple myeloma with renal impairment (RI) treated with standard of care idecabtagene vicleucel (ide-cel), as outcomes with chimeric antigen receptor (CAR) T-cell therapy are unknown in this population. RI was defined as creatinine clearance (CrCl)

Published
2023
Full Text
View/download PDF

4. Factors Associated with Refractoriness or Early Progression after Idecabtagene Vicleucel (Ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): U.S. Myeloma CAR T Consortium Real World Experience

Author

Hamza Hashmi, Doris K. Hansen, Lauren C. Peres, Omar Alexis Castaneda Puglianini, Ciara L. Freeman, Gabriel De Avila, Surbhi Sidana, Leyla O. Shune, Douglas W. Sborov, James Davis, Charlotte B. Wagner, M. Hakan Kocoglu, Shebli Atrash, Peter M. Voorhees, Gary Simmons, Christopher J. Ferreri, Nilesh Kalariya, Aishwarya Sannareddy, Danai Dima, Jack Khouri, Joseph P. McGuirk, Frederick L. Locke, Rachid C. Baz, Krina Patel, and Melissa Alsina

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

5. Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience

Author

Jack Khouri, Hong Li, Doris K. Hansen, Surbhi Sidana, Leyla O. Shune, Shaun DeJarnette, Faiz Anwer, Douglas W Sborov, Charlotte B Wagner, M. Hakan Kocoglu, Shebli Atrash, Peter M. Voorhees, Jason Valent, Lauren C. Peres, Vanna Hovanky, Gary Simmons, Danai Dima, Nilesh Kalariya, Aimaz Afrough, Gurbakhash Kaur, Aishwarya Sannareddy, Christopher J. Ferreri, James Davis, Joseph P. McGuirk, Frederick L. Locke, Rachid C. Baz, Betty K. Hamilton, Melissa Alsina, Craig S. Sauter, Hamza Hashmi, and Krina Patel

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

6. Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience

Author

Surbhi Sidana, Lauren C. Peres, Hamza Hashmi, Hitomi Hosoya, Christopher J. Ferreri, Shebli Atrash, Jack Khouri, Peter M. Voorhees, Danai Dima, Gary Simmons, Nilesh Kalariya, Vanna Hovanky, Sushma Bharadwaj, Sally Arai, David B. Miklos, Charlotte B Wagner, James Davis, Douglas W. Sborov, Taiga Nishihori, Melissa Alsina, Frederick L. Locke, Rebecca Gonzalez, M. Hakan Kocoglu, Aishwarya Sannareddy, Aimaz Afrough, Joseph P. McGuirk, Leyla O. Shune, Krina Patel, and Doris K. Hansen

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

7. Racial and Ethnic Differences in Clinical Outcomes Among Multiple Myeloma Patients Treated with CAR T Therapy

Author

Lauren C. Peres, Laura B. Oswald, Christen Dillard, Gabriel De Avila, Taiga Nishihori, Brandon J. Blue, Ciara L. Freeman, Frederick L. Locke, Melissa Alsina, Omar Alexis Castaneda Puglianini, Leyla O. Shune, Douglas W. Sborov, Charlotte B Wagner, Danai Dima, Hamza Hashmi, James Davis, M. Hakan Kocoglu, Shebli Atrash, Gary Simmons, Nilesh Kalariya, Christopher J. Ferreri, Aishwarya Sannareddy, Aimaz Afrough, Peter M. Voorhees, Jack Khouri, Joseph P. McGuirk, Surbhi Sidana, Doris K. Hansen, and Krina Patel

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

8. Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Have Received a Prior BCMA-Targeted Therapy: Real World, Multi-Institutional Experience

Author

Christopher J. Ferreri, Michelle A.T. Hildebrandt, Hamza Hashmi, Leyla O. Shune, Joseph P. McGuirk, Douglas W. Sborov, Charlotte B Wagner, M. Hakan Kocoglu, Shebli Atrash, Peter M. Voorhees, Jack Khouri, Danai Dima, Aimaz Afrough, Aishwarya Sannareddy, Gary Simmons, James Davis, Nilesh Kalariya, Lauren C. Peres, Melissa Alsina, Frederick L. Locke, Surbhi Sidana, Doris K. Hansen, Krina Patel, and Omar Alexis Castaneda Puglianini

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

9. Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM) with Renal Impairment: Real World Experience

Author

Surbhi Sidana, Lauren Peres, Hamza Hashmi, Hitomi Hosoya, Christopher Ferreri, Shebli Atrash, Jack Khouri, Peter M. Voorhees, Danai Dima, Gary Lee Simmons, Nilesh Kalariya, Vanna Hovanky, Sushma Bharadwaj, Sally Arai, David B. Miklos, Charlotte Wagner, James Davis, Douglas Sborov, Taiga Nishihori, Melissa Alsina, Frederick L. Locke, Rebecca Gonzalez, Mehmet H. Kocoglu, Aishwarya Sannareddy, Aimaz Afrough, Joseph P. McGuirk, Leyla Shune, Krina K. Patel, and Doris K Hansen

Subjects
Transplantation, Molecular Medicine, Immunology and Allergy, Cell Biology, Hematology
Published
2023

Catalog

Books, media, physical & digital resources
See catalog results